Abstract:Malaria remains a global health burden, killing over half a million people each year. Decreased therapeutic efficacy to artemisinin, the most efficacious antimalarial, has been detected in sub-Saharan Africa, a worrying fact given that over 90% of deaths occur on this continent. Mutations in Kelch13 are the most well-established molecular marker for artemisinin resistance, but these do not explain all artemisinin-resistant isolates. Understanding the biological underpinnings of drug resistance is key to curbing the emergence and spread of artemisinin resistance. Artemisinin-mediated non-specific alkylation leads to the accumulation of misfolded and damaged proteins and activation of the parasite unfolded protein response (UPR). In addition, the parasite proteasome is vital to artemisinin resistance, as we have previously shown that chemical inhibition of the proteasome or mutations in the β2 proteasome subunit increase parasite susceptibility to dihydroartemisinin (DHA), the active metabolite of artemisinins. Here, we investigate parasites with mutations at the Kelch13 and/or 19S and 20S proteasome subunits with regard to UPR regulation and proteasome activity in the context of artemisinin resistance. Our data show that perturbing parasite proteostasis kills parasites, early parasite UPR signaling dictates DHA survival outcomes, and DHA susceptibility correlates with impairment of proteasome-mediated protein degradation. Importantly, we show that functional proteasomes are required for artemisinin resistance in a Kelch13-independent manner, and compound-selective proteasome inhibition demonstrates why artemisinin-resistant Kelch13 mutants remain susceptible to the related antimalarial peroxide OZ439. These data provide further evidence for targeting the parasite proteasome and UPR to overcome existing artemisinin resistance.IMPORTANCEDecreased therapeutic efficacy represents a major barrier to malaria treatment control strategies. The malaria proteasome and accompanying unfolded protein response are crucial to artemisinin resistance, revealing novel antimalarial therapeutic strategies.

Author Correction: The artemisinin-induced dormant stages of Plasmodium falciparum exhibit hallmarks of cellular quiescence/senescence and drug resilience

The artemisinin-induced dormant stages of Plasmodium falciparum exhibit hallmarks of cellular quiescence/senescence and drug resilience

Author Correction: Aryl amino acetamides prevent Plasmodium falciparum ring development via targeting the lipid-transfer protein Pf START1

Corrigendum for “A Novel Kinase Subverts Aluminium Resistance by Boosting Ornithine Decarboxylase‐dependent Putrescine Biosynthesis”

Plasmodium falciparum artemisinin resistance: something gained in translation

Correction to "Integrated Network Pharmacology Analysis and Serum Metabolomics to Reveal the Antimalaria Mechanism of Artesunate"

Correction: Future antimalarials from Artemisia ? A rationale for natural product mining against drug-refractory Plasmodium stages

Author Correction: CaIPF14030 negatively modulates intracellular ATP levels during the development of azole resistance in Candida albicans

A dynamic stress model explains the delayed drug effect in artemisinin treatment of Plasmodium falciparum

Artemisinin-resistant K13 mutations rewire Plasmodium falciparum’s intra-erythrocytic metabolic program to enhance survival

Single cell transcriptional changes across the blood stages of artemisinin resistant K13 upon dihydroartemisinin exposure

Ring-stage growth arrest: Metabolic basis of artemisinin tolerance in Plasmodium falciparum

Corrigendum: Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma

Correction: Corrigendum: Autophagy-associated alpha-arrestin signaling is required for conidiogenous cell development in Magnaporthe oryzae

tRNA modification reprogramming contributes to artemisinin resistance in Plasmodium falciparum

Enhanced cell stress response and protein degradation capacity underlie artemisinin resistance in Plasmodium falciparum

Correction: Awad et al. Repurposing Potential of the Antiparasitic Agent Ivermectin for the Treatment and/or Prophylaxis of COVID-19. Pharmaceuticals 2022, 15, 1068

Drug-induced stress mediates Plasmodium falciparum ring-stage growth arrest and reduces in vitro parasite susceptibility to artemisinin

Multi-omics dissection of stage-specific artemisinin tolerance mechanisms in Kelch13-mutant Plasmodium falciparum

A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria

Molecular insights into artemisinin resistance in Plasmodium falciparum: An updated review